Kim Jihoon, Yoo Jae Suk, Kim Hee-Jung, Kim Ho Jin, Kim Dae-Hee, Choo Suk Jung, Kim Joon Bum
Department of Thoracic and Cardiovascular Surgery, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Republic of Korea.
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
JTCVS Open. 2023 Jun 20;15:27-37. doi: 10.1016/j.xjon.2023.06.006. eCollection 2023 Sep.
Genetic aortopathy, if left untreated, leads to aortic catastrophe in most affected individuals. We sought to determine the genetic mutation patterns and detection rates in patients with aortopathy and their families with a systematic screening protocol.
In 2016 to 2020, patients with aortic dissection or root aneurysm (Z score ≥2) and their first-degree relatives were enrolled in a prospective registry at a tertiary referral center. The individuals underwent systematic single- or multi-gene panel testing depending on clinical presentations.
Among 575 enrolled individuals (mean age, 46.6 ± 14.5 years; 203 women), 346 (60.2%) underwent genetic testing. Rates of relevant gene mutations identified were 39.4% (91/231), 27.1% (54/199) and 72.4% (n = 105) in aneurysm, dissection, and family screening groups, respectively ( < .001). Mutated genes frequently identified were (n = 199; Marfan), or (n = 14; Loeys-Dietz), (n = 15; Ehlers-Danlos), and (n = 10). After enrollment, 123 aortic surgeries were performed in 117 patients (20.3%) including 15 family members, with resultant operative mortality of 0.8% (n = 1). In logistic regression analysis, systemic score in Ghent nosology was the only significant factor associated with positive gene mutation (odds ratio, 14.81; 95% confidence interval, 6.87-31.96), and its 3.5 point cutoff showed the best predictive value with 78.2% sensitivity and 87.2% specificity.
Genetic aortopathy was identified in a considerable proportion of patients with aortopathy and their family members by systematic genetic testing. This strategy is recommended for timely diagnosis and proactive management of genetic aortopathy.
遗传性主动脉病变若不治疗,多数患者会发生主动脉灾难性后果。我们试图通过系统筛查方案来确定主动脉病变患者及其家族的基因突变模式和检出率。
2016年至2020年,主动脉夹层或根部动脉瘤患者(Z评分≥2)及其一级亲属在一家三级转诊中心纳入前瞻性登记研究。根据临床表现,这些个体接受系统的单基因或多基因检测。
在575名登记个体中(平均年龄46.6±14.5岁;203名女性),346名(60.2%)接受了基因检测。在动脉瘤组、夹层组和家族筛查组中,相关基因突变检出率分别为39.4%(91/231)、27.1%(54/199)和72.4%(n = 105)(P<0.001)。常见的突变基因有FBN1(n = 199;马凡综合征)、TGFBR1或TGFBR2(n = 14;洛伊迪茨综合征)、COL3A1(n = 15;埃勒斯-当洛综合征)和ACTA2(n = 10)。登记后,117名患者(20.3%)包括15名家庭成员接受了123次主动脉手术,手术死亡率为0.8%(n = 1)。在逻辑回归分析中,根特分类法中的全身评分是与基因突变阳性相关的唯一显著因素(比值比,14.81;95%置信区间,6.87 - 31.96),其3.5分的临界值显示出最佳预测价值,敏感性为78.2%,特异性为87.2%。
通过系统基因检测,在相当比例的主动脉病变患者及其家族成员中发现了遗传性主动脉病变。推荐采用该策略对遗传性主动脉病变进行及时诊断和积极管理。